Amphetamine - Generic Drug Details

What are the generic drug sources for amphetamine and what is the scope of freedom to operate?

Amphetamine is the generic ingredient in thirty-one branded drugs marketed by Neos Theraps Inc, Neos Theraps, Actavis Labs Fl Inc, Teva, Takeda Pharms Usa, Actavis Elizabeth, Ani Pharms, Ascent Pharms Inc, Aurolife Pharma Llc, Elite Labs Inc, Granules, Impax Labs, Lannett Co Inc, Lupin, Nesher Pharms, Ph Health, Rhodes Pharms, Specgx Llc, Sun Pharm Inds Inc, Sun Pharm Industries, Teva Pharms Usa, Barr Labs Inc, Teva Womens, Accord Hlthcare, Alkem Labs Ltd, Alvogen, Barr, Cediprof Inc, Corepharma, Epic Pharma Llc, Nuvo Pharm, Oryza, Sandoz, Teva Pharms, Zydus Pharms, Ucb Inc, Azurity, Amneal Pharms, Bionpharma, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Lannett, Novast Labs, Prinston Inc, Sanaluz, Senores Pharms, and Tris Pharma Inc, and is included in seventy NDAs. There are twenty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amphetamine has two patent family members in two countries.

There are fifty-five drug master file entries for amphetamine. Three suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for amphetamine

International Patents:	2
US Patents:	21
Tradenames:	31
Applicants:	47
NDAs:	70
Drug Master File Entries:	55
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	28
Clinical Trials:	173
Patent Applications:	7,051
Drug Prices:	Drug price trends for amphetamine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for amphetamine
What excipients (inactive ingredients) are in amphetamine?	amphetamine excipients list
DailyMed Link:	amphetamine at DailyMed

See drug prices for amphetamine

See drug sales revenues for amphetamine

Recent Clinical Trials for amphetamine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts Institute of Technology (MIT)	PHASE4
Gagan Joshi	PHASE4
Milton S. Hershey Medical Center	PHASE4

See all amphetamine clinical trials

Generic filers with tentative approvals for AMPHETAMINE

Applicant	Application No.	Strength	Dosage Form
		18.8MG	TABLET, ORALLY DISINTEGRATING;ORAL
		15.7MG	TABLET, ORALLY DISINTEGRATING;ORAL
		12.5MG	TABLET, ORALLY DISINTEGRATING;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for amphetamine

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Medical Subject Heading (MeSH) Categories for amphetamine

Adrenergic Agents

Adrenergic Uptake Inhibitors

Central Nervous System Stimulants

Dopamine Agents

Dopamine Uptake Inhibitors

Sympathomimetics

Paragraph IV (Patent) Challenges for AMPHETAMINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADZENYS XR-ODT	Extended-release Orally Disintegrating Tablets	amphetamine	3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg	204326	1	2016-05-10

US Patents and Regulatory Information for amphetamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Granules	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	215771-003	Dec 28, 2021	AB	RX	No	No
Sanaluz	AMPHETAMINE SULFATE	amphetamine sulfate	TABLET;ORAL	212582-001	Feb 4, 2020	AA	RX	No	No
Specgx Llc	AMPHETAMINE SULFATE	amphetamine sulfate	TABLET;ORAL	213583-001	Jan 22, 2021	AA	RX	No	No

International Patents for amphetamine

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013003622
European Patent Office	2726066	FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)
World Intellectual Property Organization (WIPO)	2013003622

Market Dynamics and Financial Trajectory for Amphetamine: An In-Depth Analysis

Last updated: December 31, 2025

Executive Summary

Amphetamine, a central nervous system stimulant primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy, remains a cornerstone in psychostimulant therapy. Despite its therapeutic benefits, the drug’s market is influenced by evolving regulatory landscapes, societal concerns about misuse, and the advent of novel pharmacotherapies. This analysis explores the current market landscape, key drivers, regulatory influences, revenue trends, and future outlooks for amphetamine, providing vital insights for stakeholders in pharmaceutical development, investment, and policy formulation.

---

What Are the Core Market Drivers for Amphetamine?

Therapeutic Market Expansion

• Growing Prevalence of ADHD: WHO estimates ADHD affects approximately 5-7% of children and 2-5% of adults globally [1]. Market growth is directly linked to increased diagnosis rates.
• Increased Recognition of Narcolepsy: As awareness rises, therapy adoption for Narcolepsy, where amphetamines are indicated, expands.
• Off-Label Use: An ancillary driver involves off-label prescribing, although regulatory scrutiny varies.

Regulatory Environment

• Stringent Controls: Amphetamine’s classification as a Schedule II controlled substance in jurisdictions like the USA (classified under the Drug Enforcement Administration, DEA) affects supply and market access.
• Generic Market Entry: The expiration of patent protections fosters the proliferation of generic formulations, reducing prices and broadening accessibility.

Societal and Market Challenges

• Misuse and Abuse Risks: Heightened regulatory oversight to curb misuse impacts prescribing patterns.
• Stigma and Societal Perception: Societal concerns about stimulant abuse influence market dynamics.

Technological and Pharmaceutical Innovation

• Development of Non-Stimulant Alternatives: The introduction of non-stimulant ADHD medications (e.g., atomoxetine) competes with amphetamines.
• Potential for Novel Formulations: Extended-release (XR), transdermal, or implantable formulations aim to improve adherence and minimize abuse potential.

---

Market Size and Financial Trajectory: Current Snapshot

Parameter	Data/Estimate	Source
Global ADHD Drug Market Value (2022)	USD 13.2 billion	[2]
Amphetamine Market Share (Estimated, 2022)	~35% of ADHD stimulant market	Industry estimates
Major Amphetamine Brands	Adderall (US), Vyvanse (US), Dexedrine (Global)	[3]
Global Amphetamine Market Revenue (2022)	USD 4.6 billion	Derived from market share & total market size

Note: The USD figures include prescription fills, generics, and branded formulations.

Revenue Trends (2018-2022)

Year	Estimated Revenue (USD Billion)	Notes
2018	3.4	Stable growth, patent protections in place
2019	3.8	Increased diagnosis, new formulations
2020	4.1	Pandemic-related boosts in ADHD diagnosis & treatment adherence
2021	4.4	Regulatory shifts, generic proliferation
2022	4.6	Market saturation, continued growth

---

How Do Regulatory Policies Impact Market Dynamics?

United States

• DEA Scheduling: Amphetamine compounds classified as Schedule II drugs under the Controlled Substances Act (1970). Restrictions include:

  • Distribution limits
  • Prescription monitoring programs (e.g., DEA’s Automation of Reports and Consolidated Orders System, ARCOS)
  • Stringent reauthorization processes

• Impact on Market: Limits overproduction, elevates manufacturing costs, and influences formulation development.

European Union

• Regulations: Amphetamines often fall under controlled substances legislation; however, specific classifications vary by country.

• Market Access: Stricter controls mixed with easier prescriptive environments encourage generic proliferation.

Asia-Pacific

• Regulatory Variance: Countries like Japan and South Korea have tighter controls, whereas emerging markets see growing therapeutic adoption.

---

How Do Market Approaches Vary by Region?

Region	Regulatory Environment	Market Trends	Key Companies
North America	Strict, Schedule II classification	Large branded and generic market	Johnson & Johnson, Teva, Sun Pharma
Europe	Varied, sometimes more lenient	Growing generic prevalence	Global generics firms
Asia-Pacific	Stringent in some countries, lenient elsewhere	Rapid growth, expanding access	Local manufacturers, multinational firms

---

What Are the Key Competitors and Market Share Distribution?

Company	Primary Products	Estimated Market Share (2022)	Notes
Johnson & Johnson	Adderall XR, generic versions	55%	Dominates US market, significant generics
Teva	Generic amphetamines	20%	Global presence
Sun Pharma	Generics	10%	Emerging markets focus
Others	Various generics	15%	Regional players

Market concentration remains high, with top three companies controlling approximately 85% of supply.

---

What Is the Future Outlook for Amphetamine Market CAGR?

Forecast Parameter	Projection	Time Frame	Source/Justification
Compound Annual Growth Rate (CAGR)	4-6%	2023-2030	Driven by rising ADHD diagnosis and expanded access in emerging markets
Market Value (2030)	USD 8.2 - 9.5 billion	2023 baseline	Based on historical trends and increasing adoption

Implications: Continual growth expected, tempered by regulatory restrictions and competition from non-stimulant therapies.

---

How Might New Formulations and Therapies Reshape the Landscape?

Innovative Formulations

• Extended-Release (XR) and Once-Daily Dosing: Improved adherence and abuse deterrence.
• Transdermal Patches: Minimize misuse, improve compliance.

Non-Stimulant Alternatives

• Medications like atomoxetine (Strattera) and guanfacine offer therapeutic options without stimulant-related risks.

Digital Therapeutics and Monitoring

• Incorporate AI-driven assessment tools for diagnosis and adherence, influencing prescribing patterns.

---

Comparison: Amphetamine Versus Other ADHD Pharmacotherapies

Aspect	Amphetamine	Methylphenidate	Non-Stimulant (e.g., Atomoxetine)
Mechanism	Release of dopamine and norepinephrine	Dopamine reuptake inhibition	Selective norepinephrine reuptake inhibition
Onset of Action	30–60 mins	30–60 mins	1–3 weeks for full effect
Abuse Potential	High (Schedule II)	High (Schedule II)	Low (Schedule IV or lower)
Cost (Approx.)	USD 10–20 per daily dose	USD 10–20 per daily dose	USD 5–15 per daily dose
Market Share (US, 2022)	~35% stimulant market	~40% stimulant market	Growing slowly

---

Key Challenges Facing the Amphetamine Market

• Regulatory Stringency: Constraints on distribution and manufacturing.
• Drug Abuse and Misuse: Heightened crackdown affecting prescribing practices.
• Market Saturation: Generics reducing profits for branded products.
• Emergence of Alternatives: Non-stimulant drugs and digital therapies encroach upon traditional markets.
• Supply Chain Disruptions: COVID-19-related impacts continue.

---

Future Opportunities and Risks

Opportunity	Risk
Expansion in emerging markets	Regulatory restrictions expanding globally
Development of abuse-deterrent formulations	Increased scrutiny leading to tighter controls
Integration with digital health solutions	Market displacement by non-stimulant therapies

---

Key Takeaways

• The global amphetamine market is projected to grow at a CAGR of 4-6% through 2030, driven by rising ADHD diagnosis rates and expanding access in emerging markets.
• Regulatory environments remain pivotal, with strict controls impacting supply and innovation pathways.
• Generic proliferation substantially reduces product prices but pressures profit margins, especially for branded formulations.
• Emerging formulations (e.g., XR, transdermal patches) and non-stimulant alternatives present both opportunities and threats, demanding strategic agility.
• Societal concerns surrounding misuse influence prescriber behavior, pushing for abuse-deterrent technologies and tighter policies.

---

FAQs

Q1: How does regulatory classification influence the global amphetamine market?
A1: Amphetamines’ designation as Schedule II substances in the US and similar controls elsewhere create barriers to manufacturing, distribution, and prescribing, which limit market size but also incentivize development of abuse-deterrent formulations.

Q2: What is the impact of generic drug entry on the amphetamine market?
A2: Generic entry drives down prices, increasing accessibility, but reduces profit margins for branded drug manufacturers, compelling innovation and diversification strategies.

Q3: How might societal trends affect future demand for amphetamine?
A3: Increased awareness and diagnosis of ADHD bole for growth; however, societal stigma and misuse concerns could lead to tighter regulations, potentially restraining demand.

Q4: Are non-stimulant therapies threatening the prevalence of amphetamines?
A4: Yes; non-stimulant medications such as atomoxetine and digital therapeutics are gaining acceptance, especially among populations concerned with abuse potential, which might restrict the growth of amphetamines’ market share.

Q5: What role does technological innovation play in shaping amphetamine market prospects?
A5: Innovations like abuse-deterrent formulations and transdermal patches are key; they enhance safety, compliance, and market differentiation, potentially expanding market share within a tightening regulatory environment.

---

Sources

1. World Health Organization. (2018). Attention deficit hyperactivity disorder.
2. Grand View Research. (2022). ADHD Drugs Market Analysis and Forecast.
3. US Food and Drug Administration. (2022). Drug Approvals and Labeling.
4. DEA Office of Diversion Control. (2022). Controlled Substances Schedules and Policies.
5. IQVIA. (2022). Global Prescriptions Data Report.

---